 |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 ...
|
 |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such ...
|
 |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat ...
|
 |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide ...
|
 |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a ...
|
 |
February 21, 2011
Prof Valeria Santini talks about the results of her research on the use of comorbidity indexes to determine prognosis for elderly myelodysplastic syndrome patients treated with azacitidine. This ...
|
 |
February 21, 2011
The groundbreaking introduction of the tyrosine kinase inhibitor (TKI) imatinib as a treatment for chronic myeloid leukaemia (CML) has been followed by the introduction of further second and third ...
|
 |
February 21, 2011
Prof George Canellos talks about the key research that has emerged from the 2010 ASH meeting in Florida. One trial of note compared the Stanford V treatment regimen with ABVD for patients with ...
|
 |
February 18, 2011
Prof Timothy Hughes speaks to ecancer.tv about the ENESTnd trial which is evaluating the efficacy and safety of the second generation tyrosine kinase inhibitor nilotinib in newly diagnosed chronic ...
|
 |
February 18, 2011
Dr Reinhard Stauder speaks about his aims for the upcoming ecancer meeting on haematological cancers in elderly patients, Rome, 18-20th March 2011. This meeting will address the difficulties ...
|
 |
February 18, 2011
Dr Michael Keating discusses his pick of the research presented at ASH 2010. This includes trials looking at new tyrosine kinase inhibitors that target LIM-kinase, Syk, PI 3-kinase delta or BTK. ...
|
 |
February 18, 2011
Prof Kanti Rai discusses advances that have been made in the treatment of chronic lymphocytic leukaemia (CLL). Key research presented at this years ASH congress has demonstrated that previously ...
|
 |
February 18, 2011
Prof Pieter Sonneveld speaks about a trial evaluating the efficacy of bortezomib during induction and maintenance therapy on progression-free survival in patients with multiple myeloma. A higher ...
|
 |
February 18, 2011
Prof Wyndham Wilson provides a comprehensive summary of the key lymphoma related research presented at the 2010 ASH congress in Florida. The first study discussed demonstrates that treating ...
|
 |
February 18, 2011
Dr William Matsui speaks about plasma cell biology and how this affects cancer growth. In multiple myeloma, malignant plasma cells make up the vast majority of tumour cells and are thought to be ...
|
 |
February 18, 2011
Jan Geissler speaks about some of the key research into chronic myeloid leukaemia (CML) that has been presented at ASH 2010. This includes papers on the second generation tyrosine kinase ...
|
 |
February 18, 2011
Jan Geissler speaks about the upcoming ecancer meeting on haematological cancers in the elderly which will be held in Rome, 18-20th March 2011. This meeting will tackle issues such as the ...
|
 |
February 18, 2011
Dr Jerald Radich speaks about the treatment options that are available for chronic myeloid leukaemia (CML). Tyrosine kinase inhibitors such as imatinib dasatinib and erlotinib have allowed to ...
|
 |
February 18, 2011
Prof Stephen Baylin speaks to ecancertv about epigenetics. He explains what epigenetics is, how it is being used to treat cancer and how it may potentially be used in the future. Prof Baylin ...
|
 |
February 18, 2011
Prof Giuseppe Saglio speaks about the DASISION trial which compares dasatinib with imatinib as initial treatment for patients with newly diagnosed chronic myeloid leukaemia in chronic phase ...
|
|
|
|
|
|
Featured
Content
Featuring websites that enhance the internet user’s experience.
|